Multiple Myeloma: Recent Advances in Diagnosis, Analysis and Therapeutic Management: 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 February 2026 | Viewed by 583
Special Issue Editor
Interests: hematologic malignancies; multiple myeloma; next generation sequencing; molecular heterogeneity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Many studies have demonstrated multiple myeloma (MM) to be a complex and heterogeneous disease with many genetic events that impact patients’ prognoses. Next-generation sequencing allows for the understanding and classification of MM’s genomic landscape in which the presence of “high-risk” features keeps predicting poorer outcomes regardless of the effectiveness of novel treatments. Multiple myeloma is thus still considered incurable, although recent clinical trials have shown promising results regarding the stabilization of the disease, furthering the five-year threshold. However, many features still require consideration with the rise in improved disease monitorization through minimal residual disease analysis and its association with relapse probability.
This is the second edition of this Special Issue. We welcome research articles and review papers that focus on a wide scope of multiple myeloma, ranging from basic pathology to preclinical and clinical studies. You may read the publications in the first edition at Multiple Myeloma: Recent Advances in Diagnosis, Analysis and Therapeutic Management.
Dr. Juan Manuel Rosa-Rosa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma (MM)
- hematologic malignancies
- next-generation sequencing
- heterogeneous disease
- tumor heterogeneity
- genomic landscape
- outcomes
- novel treatments
- clinical trial
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
